Abstract
Cytochrome P450 2D6 (CYP2D6) is involved in metabolising over 20% of clinical drugs, yet its genetic variation across ancestries is underexplored in large-scale whole-genome sequencing (WGS) datasets. We analysed WGS data from 479,144 UK Biobank participants, identifying 95 distinct CYP2D6 star alleles across five biogeographic groups. Of these, 48 alleles had currently unknown effects. These alleles were more prevalent in African, admixed American, and South Asian groups (∼5%) compared to European and East Asian groups (∼2%), affecting the ability to provide pharmacogenomics recommendations across ancestries. We identified 99,656 (20.8%) individuals carrying CYP2D6 structural variations and predicted the CYP2D6 ultra-rapid metaboliser phenotype to be most common in Africans (4.5%) and rarest in East Asians (0.32%). Less than half (45.7%) of rare protein-truncating variant carriers were categorised as poor or intermediate metabolisers, indicating an underrepresentation of rare functional variants in the current CYP2D6 star allele evaluation. Phenome-wide association studies confirmed links with narcotic allergies and found new associations with plasma BAFFR and BAFF proteins, offering insights for the BAFF-targeted clinical therapy. Collectively, this largest WGS study of CYP2D6 to date highlights the importance of leveraging all genetic variations for pharmacogenomic insights affecting therapeutic safety and development.
Competing Interest Statement
X.J., F.H., X.Z.Z., A.A., S.V.V.D., S.S.A., G.A., A.O., J.H., M.F., Q.W., S.P., O.B., K.R.S. are current employees and/or stockholders of AstraZeneca. W.R. is a current employee and stockholder of Alexion Pharmaceuticals Inc.
Funding Statement
X.J., F.H., X.Z.Z., A.A., S.V.V.D., S.S.A., G.A., A.O., J.H., M.F., Q.W., S.P., O.B., K.R.S. are current employees and/or stockholders of AstraZeneca. W.R. is a current employee and stockholder of Alexion Pharmaceuticals Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank data were available via the registration for access procedure described at https://www.ukbiobank.ac.uk/enable-your-research. Our Resource Application Number is 26041.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data and code availability
The UK Biobank data were available via the registration for access procedure described at https://www.ukbiobank.ac.uk/enable-your-research. Association tests described in this study were performed using a custom framework, PEACOK (PEACOK 1.0.7), that is available via GitHub (https://github.com/astrazeneca-cgr-publications/PEACOK/).
